SGLT2 inhibitors are one of many medicines you may take to treat type 2 diabetes. They also can protect your kidneys and make heart failure less likely. (Photo Credit: Moment RF/Getty Images) SGLT2 ...

In a retrospective study, repetitive transcranial magnetic stimulation produces weight loss comparable to semaglutide 0.5 ...

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...

The use of SGLT2 inhibitors, especially dapagliflozin, can lower adiposopathy parameters in patients with CKD, regardless of ...

A major pooled analysis published in JAMA has shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors deliver consistent ...

Please provide your email address to receive an email when new articles are posted on . GLP-1 receptor agonists conferred greater HbA1c reductions in older adults than younger adults. Older adults had ...

A recent review examined how widely used treatments such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists may affect cancer growth.

SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis. After adjustments, patients on SGLT2 inhibitors had a significantly reduced risk of progression to severe ...

Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed. The combined 12-month risk for myocardial infarction (MI), ...

Please provide your email address to receive an email when new articles are posted on . Treatment with sodium-glucose cotransporter-2 inhibitors for type 2 diabetes may reduce the risk for rheumatoid ...

Researchers evaluate the lifetime cost-effectiveness of using SGLT2 inhibitors or GLP1 receptor agonists as first-line treatments for type 2 diabetes. Use of sodium-glucose cotransporter-2 (SGLT2) ...